A forgotten history of common injustice: 1000 ISF dismissed "in silence" and in general indifference.

Fedaisf editorial staff

November 17, 2018

A forgotten story of common injustice: 1000 workers fired "in silence" and in general indifference. Not due to a state of crisis but due to a history of bad money, false business transfer agreements and fraudulent bankruptcy. Meanwhile, justice is slow to arrive…

Dal Blog Avv. Rosanna De Leo – 13 novembre 2018

At a time when there is so much talk about Justice, Processes and prescriptions, nobody seems to be interested in the life story of about 1000 Pharmaceutical Representative workers who lost their jobs 7 years ago not because of the economic "crisis". but for a bad story of money, multinationals and fraudulent bankruptcy.

Approximately 400 of these Pharmaceutical Representatives have heroically denounced the wrongdoings concocted behind their backs by some Big Pharma, with the endorsement of the Unions (which had induced them to sign Conciliation Reports in a "protected forum" to silence everything). In 2013, the Public Prosecutor's Office of Milan, after a thorough investigation and reconstruction of the facts, requested the indictment of about 20 people, including directors of some well-known multinational drug companies, lawyers and consultants.

I am referring to the "crash" of the pharmaceutical company Marvecspharma Service srl, based in Milan (share capital € 12,000.00), established in the late 1990s with about 30 employees which, between 2004 and 2007 had acquired about 1,200 informants Pharmaceutical Scientists, through "sales of business units" organized by various drug multinationals and in particular by the Pfizer Italia srl and from Astrazeneca SpA And Simesa SpA In practice, the Big Pharmas had "sold" their workforce, with "regular" notarial contracts for the sale of the business unit, at the symbolic price of € 1,000, only to then pay several million Euros to the transferee Marvecspharma Service srl in title of "badwill"; all this, being fully aware that the latter company was not able to bear the burdens and costs deriving from these conspicuous acquisitions of personnel, since it had, since 2002, suffered serious losses in the financial statements.

The unfortunate ISF were made to sign a Trade Union Conciliation Report, which guaranteed a 36-month stability pact with the assignee Company and a minimum sum as an "incentive", against their incontrovertible renunciation of taking action against the Big Pharma for any matter related to the past and the future.

In reality it happened that, a few months after the last of the acquisitions in September 2007, Marvecspharma Service declared a state of crisis, first placing the workers in CIGS and then no longer paying wages, until it reached bankruptcy in January 2011 , with the end result that about 1000 people were left without a job.

Basically, the drug multinationals (Pfizer Italia srl and Astrazeneca SpA in the lead) with the aforementioned operations, had unloaded the weight and "shame" of the layoffs on Marvecspharma Service srl, in order to remain "pure and immaculate” per il mercato, gli azionisti e le società di rating. Le suddette Società, peraltro, non avrebbero potuto in ogni caso, accedere alle normali procedure di licenziamento collettivo di cui alla L. 223/91: in fact, none of the Big Pharmas involved has ever been in a crisis, so much so as to justify a collective mobility procedure which, moreover, would have foreseen greater economic burdens for it. Furthermore, the activation of a collective redundancy would not have made possible the concomitant financial operations of merger/acquisition of other companies.

Therefore, the absolute protection of profits/dividends/profits prevailed over the protection of workers, who were left without employment, all aged between 35 and 60, with difficulty in relocating to the labor market.

La Procura della Repubblica di Milano, come detto, ha scoperchiato questo malsano meccanismo (Procedimento n. 10147/2011 R.G. N.R.) rinviando a giudizio tutti gli ex amministratori della Pfizer Italia s.r.l., di Astrazeneca S.p.A e di Simesa S.p.A. La stampa aveva dato notizia dell’apertura di quel processo, nel lontano 2014 … e poi?

What happened after?

Some defendants and, among them all the former directors of Pfizer, Astrazeneca and Simesa, had asked to be judged with the abbreviated procedure, while the others with the ordinary rules of the trial.

Well the fact is that the abbreviated procedure, pending before the GUP of Milan (Dr. Pepe) is still inexplicably pending, malgrado siano esaurite tutte le arringhe e requisitorie da oltre un anno. Ad ogni udienza vengono chiesti e concessi rinvii … l’ultimo il 30 ottobre… udienza rinviata al 17.12.2018… e alla fine ci sarà finalmente la sentenza?

Result: the 400 workers are still awaiting a ruling which, they hope, will at least give them justice for the loss of their job, the impossibility of relocating, of retiring, of the loss of foreclosed houses due to the inability to pay mortgages of broken and separated families.

These people have been scammed and have lost their jobs and dignity not due to a company and market crisis, but only to satisfy the profit and market logic of the drug multinationals who have dumped them in the MarvecsPharma Service srl "garbage bin".

Several times, over the years, we have tried to involve the press, but apart from the news of the opening of the trial back in 2014, then there was oblivion, indifference, with the unpleasant feeling that the interests of ISF workers, who have been subject to exchange, the base price of the "transfer" does not interest ai average.

Yet behind each of those names lies the story of a life, suffering, the art of getting by for survival, lies the disease that struck someone and the death of those who didn't make it. and in the meantime we helplessly watch the performance of the Abbreviato which is not abbreviated but an “extended” rite!!!

The media should deal with these stories, the distortions of a justice system that are poured on the skin of citizens who are waiting, even if only, for a moral victory.

A former Marvecspharma employee

Luigi Signorile

Comunico che la Corte di Cassazione con due importanti pronunce del 24 e 25 gennaio 2018 ha dichiarato la illegittimità della cessione di ramo di azienda di Astrazeneca S.p.A. del settembre 2007, con ciò aggiungendo un importante tassello per i giudizi di lavoro.

Venendo ai procedimenti penalties in corso comunico quanto segue:

DIBATTIMENTO nei confronti degli imputati della Marvecspharma Service s.r.l.: all’udienza del 6 febbraio 2018 sono stati ascoltati tre testi della difesa dei fratelli Danzo nonché Maurizio ROLLERO, uno degli imputati del processo ed ex amministratore della Marvecs. Il procedimento sta andando avanti senza intoppi e si avvia alla conclusione, con la conferma del quadro criminoso della bancarotta fraudolenta.

Queste sono le successive udienze dibattimentali:

29 Maggio ore 10,00 : saranno sentiti DANZO Nicola, FORRESTER e altri due testi, ovvero i consulenti di parte dei Danzo.
12 giugno 2018 : è l’udienza dedicata alle parti civili e quindi a noi! Provvederò a depositare le conclusioni con un memoria scritta e a discutere oralmente la causa. Sarebbe opportuno- per chi potrà- essere presente alla predetta udienza.
10 luglio 2018: sarà l’udienza conclusiva del dibattimento , con la requisitoria del Pubblico Ministero e le arringhe della difesa degli imputati. Secondo quanto riferito dal Presidente del Collegio , il 10 luglio dovrebbe concludersi il dibattimento con la lettura della sentenza, salvo che vi possa essere un breve slittamento di qualche settimana.
Rito ABBREVIATO : le note dolenti ! Mi sono recata presso la segreteria del GUP, per cercare di capire i motivi dei continui rinvii. In realtà -benché singolare- pare sia una prassi di quel giudice, di decidere in tempi non brevi,ma per fortuna, quasi sempre con sentenze di condanna. La prossima udienza ci sarà il 9 aprile 2018 alle ore 10.00 per sentire il Consulente della Procura, Dott. Marcozzi in merito non alle cessioni di ramo di azienda, bensì alle operazioni finanziarie più tecniche ,poste in essere dagli altri due imputati Pretti e Zambelli, consulenti finanziari della Marvecspharma , che hanno scelto anche loro il rito abbreviato.

Best regards

Avv. Rosanna de Leo